DICE

DICE Therapeutics, Inc. (DICE) | Rumor.io

DICE Therapeutics

DICE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about DICE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jun 23

DICE Therapeutics, Inc. ($DICE) has been acquired by Eli Lilly and Company ($LLY) in a deal that is seen as a strategic move in the biotech space.
The acquisition is part of a larger trend of Initial New Investment (INI) acquisitions, and has led to a significant increase in $DICE's stock price, nearing a 3x increase from its IPO.
Analysts have downgraded $DICE to "Neutral" by several firms, including Guggenheim, HC Wainwright, and Cantor Fitzgerald, citing concerns about the company's valuation and future prospects.

Generated by AI

Sentiment

Of the messages about DICE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	73.68% -26.32
Bearish	—	—	—	26.32% +26.32

Bullish· Jun 20

Eli Lilly's acquisition of DICE Therapeutics at $48 per share in cash represents a 42% premium to the stock's last close, with an aggregate deal value of approximately $2.4 billion.
DICE Therapeutics' pipeline is primarily in phase 2 or below, with one approved drug expected to generate significant revenue in the billions, potentially leading to further price appreciation.
Insiders have a high percentage of total shares in DICE, with heavy buying activity in the past, indicating a strong level of confidence in the company's prospects.

Bearish· Oct 18

The bid-ask spread for DICE Therapeutics is huge, indicating a lack of liquidity and potentially leading to a sharp price drop.
The company's chart is showing bearish signals, with the stock fading to dust and bulls in denial about the situation.
The offering price for DICE Therapeutics was too high, potentially harming investors, and the stock is now facing a significant gap to fill before it can recover.

Generated by AI

Topics

Of the messages about DICE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Oct 11

DICE Therapeutics has seen a significant price increase, with analysts raising their price targets to as high as $77.
Analysts are optimistic about the company's oral IL-17 approach, citing positive Phase 1 data and a clear proof of concept in psoriasis.
Evercore ISI and SVB Leerink have raised their price targets to $75 and $77, respectively, with both maintaining an Outperform rating.

Announcements· Jun 21

Eli Lilly agreed to acquire Dice Therapeutics for $2.4 billion in cash, with the acquisition expected to close in Q3 2023.
The deal is centered around Dice Therapeutics' oral IL-17 inhibitor programs for psoriasis, which are expected to expand Eli Lilly's immunology treatment portfolio.
Dice Therapeutics' share price soared nearly 40% following the acquisition announcement, with the company's market value increasing significantly.

Technical Analysis· Oct 11

$DICE's RSI is over 88, indicating it may be overbought and due for a substantial drop.
A possible extension target for $DICE is 54.55 or 58-60 zone, but it needs to hold its momentum.
$DICE has broken its all-time high and is trading above 40.50, with bulls seeking to establish a 5-minute uptrend to set the hourly higher lower above 22.21.

Generated by AI

Community

Of the messages about DICE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	84.54%
Newcomers	0%	0%	0%	15.46%

Regulars· Jun 20

The $2.4 billion acquisition of DICE Therapeutics by Eli Lilly is driven by the pharma's interest in the company's oral IL-17 molecules, which complement Lilly's existing psoriasis treatment Taltz.
DICE Therapeutics' pipeline offers clinical-stage psoriasis drugs in a patient-preferred pill form, complementing Lilly's existing injectable treatment.
DICE Therapeutics' stock has surged +37.1% since the previous close, reaching a new 52-week high at $46.73, driven by the acquisition news and positive market sentiment.

Newcomers· Jun 21

Eli Lilly and Company is acquiring DICE Therapeutics for $2.4 billion, with the deal expected to close in Q3 2023.
The acquisition is expected to strengthen Eli Lilly's presence in the treatment of autoimmune diseases, a field where they lag behind their competitors.
The acquisition has led to a 37.19% increase in DICE Therapeutics' share price, with analysts suggesting a bullish outlook for the stock.

Generated by AI

Also Discussed

Investors talking about DICE also mention

#	Name	Attention
1	DAWN - Day One Biopharmaceuticals, Inc.	——
2	Acumen Pharmaceuticals, Inc.ABOS	0%new
3	Vaxcyte Inc.PCVX	0%0
4	Pharvaris N.V. Ordinary SharesPHVS	0%0
5	Inhibrx Biosciences, Inc.INBX	0%0
6	ISEE - IVERIC bio, Inc.	——
7	Nkarta, Inc.NKTX	0%0
8	RETA - Reata Pharmaceuticals, Inc.	——
9	Vera Therapeutics Inc.VERA	0%new
10	Pliant Therapeutics Inc.PLRX	0%0